Protibea Therapeutics Inc.

Overview

Dysregulation of the innate immune system is now seen to play a role in many chronic disease states. The TH1 and TH2 responses are two distinct pathways that regulate defense mechanisms while maintaining immune homeostasis. Their roles and interactions are critical for balancing appropriate pro-inflammatory and anti-inflammatory responses.

When the TH1 response dominates, the result triggers autoimmune diseases, chronic systemic and neurological inflammation and tissue damage. TH2 dominance leads to allergies, asthma, eczema, impaired defense against viruses and fibrosis.

Our focus is on TH1 dominance, which is characterised by overexpression of proinflammatory cytokines that, over time, disrupt the function of critical cellular processes that are responsible for the integrity of various organ systems, particularly the central nervous system.

Our research is focussed on restoring TH1/Th2 balance, thereby creating a novel approach to managing several disorders.

Disclaimer: This website includes forward-looking statements regarding Protibea Therapeutics Inc and the development, activity, therapeutic potential, commercial potential and safety of its potential therapy for people with Alzheimer’s disease. Any statement describing the goals, expectations, financial or other projections, intentions or beliefs of Protibea Therapeutics Inc. is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.

© Protibea Therapeutics Inc. 2025 All rights reserved.